Tiziana Life Sciences (TLSA) Competitors $2.06 +0.13 (+6.74%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSA vs. SION, TRVI, URGN, CRON, IMNM, QURE, PGEN, AKBA, AVXL, and NRIXShould you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Sionna Therapeutics (SION), Trevi Therapeutics (TRVI), Urogen Pharma (URGN), Cronos Group (CRON), Immunome (IMNM), uniQure (QURE), Precigen (PGEN), Akebia Therapeutics (AKBA), Anavex Life Sciences (AVXL), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. Tiziana Life Sciences vs. Its Competitors Sionna Therapeutics Trevi Therapeutics Urogen Pharma Cronos Group Immunome uniQure Precigen Akebia Therapeutics Anavex Life Sciences Nurix Therapeutics Tiziana Life Sciences (NASDAQ:TLSA) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership. Does the media favor TLSA or SION? In the previous week, Sionna Therapeutics had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 3 mentions for Sionna Therapeutics and 2 mentions for Tiziana Life Sciences. Sionna Therapeutics' average media sentiment score of 0.81 beat Tiziana Life Sciences' score of 0.46 indicating that Sionna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sionna Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, TLSA or SION? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$11.86MN/AN/ASionna TherapeuticsN/AN/A-$61.69MN/AN/A Do analysts rate TLSA or SION? Sionna Therapeutics has a consensus target price of $38.50, indicating a potential upside of 58.83%. Given Sionna Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sionna Therapeutics is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TLSA or SION more profitable? Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Sionna Therapeutics N/A N/A N/A SummarySionna Therapeutics beats Tiziana Life Sciences on 5 of the 6 factors compared between the two stocks. Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSA vs. The Competition Export to ExcelMetricTiziana Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$240.82M$3.09B$5.82B$9.75BDividend YieldN/A2.23%3.84%4.09%P/E RatioN/A21.0131.1425.96Price / SalesN/A396.98475.48122.90Price / CashN/A43.0937.1558.38Price / Book51.508.069.116.38Net Income-$11.86M-$54.72M$3.26B$265.56M7 Day Performance4.57%2.30%1.94%1.81%1 Month Performance27.16%7.21%4.91%1.14%1 Year Performance64.80%12.85%31.21%20.98% Tiziana Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSATiziana Life Sciences0.6798 of 5 stars$2.06+6.7%N/A+52.6%$240.82MN/A0.008SIONSionna Therapeutics1.9269 of 5 stars$21.39+2.7%$38.50+80.0%N/A$918.99MN/A0.0035High Trading VolumeTRVITrevi Therapeutics3.1263 of 5 stars$7.45-0.9%$20.38+173.5%+166.5%$915.76MN/A-17.7420Analyst ForecastURGNUrogen Pharma4.5848 of 5 stars$19.40-1.6%$31.43+62.0%+33.0%$911.87M$90.40M-5.84200CRONCronos Group0.9767 of 5 stars$2.53+6.8%N/A+7.1%$907.80M$117.61M50.60450IMNMImmunome1.9847 of 5 stars$10.25-0.3%$23.14+125.8%-34.5%$894.82M$9.04M-3.3340Positive NewsAnalyst ForecastGap UpQUREuniQure2.6882 of 5 stars$15.66-3.2%$37.45+139.2%+121.2%$887.75M$14.34M-3.99500Analyst RevisionPGENPrecigen3.9134 of 5 stars$2.95+0.3%$6.00+103.4%+205.9%$876.04M$3.92M-7.02190News CoverageAnalyst ForecastOptions VolumeAnalyst RevisionAKBAAkebia Therapeutics3.9351 of 5 stars$3.11-4.3%$6.75+117.0%+114.1%$861.72M$203.73M-18.29430AVXLAnavex Life Sciences3.9212 of 5 stars$9.59-3.5%$44.00+358.8%+50.4%$854.21MN/A-16.8240Analyst ForecastNRIXNurix Therapeutics2.3985 of 5 stars$10.20-3.6%$28.87+183.0%-59.6%$808.83M$54.55M-3.91300High Trading Volume Related Companies and Tools Related Companies SION Competitors TRVI Competitors URGN Competitors CRON Competitors IMNM Competitors QURE Competitors PGEN Competitors AKBA Competitors AVXL Competitors NRIX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access